Trimerbody formating services

The plug-and-play nature of LeadArtis technology enables the rapid creation of more powerful, more effective antibodies by simply incorporating the binding domains of pre-existing antibodies to the selected Trimerbody scaffold of our structure-based design. So far, all selected antigen binding domains incorporated into the Trimerbody scaffold have dramatically enhanced biological function compared to the parental antibody. A growing pipeline could be based on this approach to creating differentiated antibody drug candidates.
 
LeadArtis’s broad portfolio of Trimerbody formats are compatible with nearly any conventional antibody, single domain antibody or antibody mimetic. Trimerbody formatting provides enhanced performance in therapeutic antibody programs in preclinical and clinical development for the treatment of cancer, inflammatory and autoimmune disorders.
 
LeadArtis extends the use of the Trimerbody technology through licenses to interested partners. For instance, some partners advancing programs in clinical trials and numerous pre-clinical projects might consider Trimerbody as a backup program to reduce toxicity, extend circulatory half-life, improve stability and solubility, or add new binding domains (e.g. addition of tumor targeting) 

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...